Advertisement

Sexually Transmitted Infections

  • Tara Lee Frenkl
  • Jeannette M. Potts
Chapter
Part of the Springer Specialist Surgery Series book series (SPECIALIST)

Abstract

The transmission of certain infectious diseases occurs most efficiently via contact of mucous membranes, and therefore, are commonly spread by sexual contact. Early lesions mainly occur on the genitalia and therefore the urologist is the first physician to assess a patient with a sexually transmitted infection (STI). Urologists play an important role in the detection, treatment, and prevention of STIs. If left untreated, STIs may have devastating local and systemic consequences.

Keywords

Human Papilloma Virus Sexually Transmitted Infection Genital Wart Genital Herpes Human Papilloma Virus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
  2. 2.
    Mawhorter SD. Travel medicine for the primary care physician. Cleve Clin J Med. 1997;64(9):483-492PubMedGoogle Scholar
  3. 3.
    Mabey D. Peeling RW: lymphogranuloma venereum. Sex Trans Infect. 2002;357:1831-1836Google Scholar
  4. 4.
    DiCarlo RP, Martin DH. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis. 1997;25(2):292-298PubMedCrossRefGoogle Scholar
  5. 5.
    Brugha R, Keersmaekers K, Renton A, Meheus A. Genital herpes infection: a review. Int J Epidemiol. 1997;26(4):698-709PubMedCrossRefGoogle Scholar
  6. 6.
    Langenberg AG, Corey L, Ashley RI, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chron HSV Vaccine Study Group. N Engl J Med. 1999;341:1432-1438PubMedCrossRefGoogle Scholar
  7. 7.
    Wald A, Brown Z. ACOG Practice Bulletin No. 57. Gynecol Herpes Simplex Virus Infect. 2004;104(5):1111-1117Google Scholar
  8. 8.
    Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121:847-854PubMedGoogle Scholar
  9. 9.
    Filen F, Strand A, Allard A, Blumberg J, Herrmann B. Duplex real-time polymerase chain reaction assay for detection and quantification of herpes simplex virus type 1 and herpes simplex virus type 2 in genital and cutaneous lesions. Sex Transm Dis. 2004;31:331-336PubMedCrossRefGoogle Scholar
  10. 10.
    Ramaswamy M, McDonald C, Smith M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect. 2004;80:406-410PubMedCrossRefGoogle Scholar
  11. 11.
    Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis. 2002;35(S2):S173-S182PubMedCrossRefGoogle Scholar
  12. 12.
    Morrow RA, Friedrich D, Krantz E, et al. Development and use of a type-specific antibody avidity test based on herpes simplex virus type 2 glycoprotein G. Sex Transm Dis. 2004;31(8):508-515PubMedCrossRefGoogle Scholar
  13. 13.
    Schmidt GP. Treatment of chancroid. Clin Infect Dis. 1999;28(Sup1):S14-S20CrossRefGoogle Scholar
  14. 14.
    Hart G. Syphilis tests in diagnostic and therapeutic decision making. Ann Intern Med. 1986;104:368-376PubMedGoogle Scholar
  15. 15.
    Hicks CB, Benson PM, Lupton GP, et al. Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus with Kaposi Sarcoma: a diagnostic dilemma. Ann Intern Med. 1987;107:492-495PubMedGoogle Scholar
  16. 16.
    Erbelding EJ, Vlahov D, Nelson KE, et al. Syphilis serology in human immunodeficiency virus infection: evidence for false negative fluorescent treponemal testing. J Infect Dis. 1997;17:1397-1400CrossRefGoogle Scholar
  17. 17.
    Brown ST Zaidi A, Larsen SA, Reynolds GH. Serologic response to syphilis treatment. J Am Med Assoc. 1985;253:1296-1299CrossRefGoogle Scholar
  18. 18.
    Calonge N. Screening for syphilis infection: recommendation statement. U.S. Preventive Services Task Force. Ann Fam Med. 2004;2:362-365PubMedCrossRefGoogle Scholar
  19. 19.
    Rees E. Treatment of pelvic inflammatory disease. Am J Obstet Gynecol. 1980;138:1042-1047PubMedGoogle Scholar
  20. 20.
    Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334:1362-1366PubMedCrossRefGoogle Scholar
  21. 21.
    Centers for Disease Control. Laboratory guidelines screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae Infections. Morb Mortal Wkly Rep. 2002;51(RR-15):10Google Scholar
  22. 22.
    Van der Pol B, Martin DH, Schachter J, et al. Enhancing the specificity of the COBAS AMPLICOR CT/NG test for Neisseria gonorrhoeae by retesting specimens with equivocal results. J Clin Microbiol. 2001;39:3092-3098CrossRefGoogle Scholar
  23. 23.
    CDC. Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. April 13, 2007;56(14):332-336Google Scholar
  24. 24.
    Frydenberg M, Malek RS. Human papilloma virus infection and its relationship to carcinoma of the penis. Urol Ann. 1993;7:185-198Google Scholar
  25. 25.
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19PubMedCrossRefGoogle Scholar
  26. 26.
    Frisch M, Glimelius B. van deen Brule AJ et al: Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350-1358PubMedCrossRefGoogle Scholar
  27. 27.
    Kulasingham SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. J Am Med Assoc. 2002;288:1749-1757CrossRefGoogle Scholar
  28. 28.
    Arican O, Suneri F, Bilgie K, et al. Topical imiquimod 5% cream in external genital warts: a randomized, double-blind, placebo-controlled study. J Dermtol. 2004;31(8):627-631Google Scholar
  29. 29.
    Langley PC, Tyring SK, Smith MH. The cost effectiveness of patient applied versus provider administered intervention strategies for the treatment of external genital warts. Am J Manag Care. 1999;5(1):69-77PubMedGoogle Scholar
  30. 30.
    Perry CM, Lab HM. Topical Imiquod: a review of its use in genital warts. Drugs. 1999;58:375-390PubMedCrossRefGoogle Scholar
  31. 31.
    Wiley DJ, Doughlas J, Beutner K, et al. External genital warts: diagnosis, treatment and prevention. Clin Infect Dis. 2002;35:S210-S224PubMedCrossRefGoogle Scholar
  32. 32.
    FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)MMWR 59(20);626-629PubMedCrossRefGoogle Scholar
  33. 33.
    U.S. Preventative Services Task Force. Screening for gonorrhea: recommendation statement. Ann Fam Med 2005;3;263-7Google Scholar
  34. 34.
    CDC. Sexually Transmitted Diseases Treatment Guidelines 2010. MMWR 2010. 59(RR-12):49Google Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Tara Lee Frenkl
    • 1
  • Jeannette M. Potts
    • 2
  1. 1.Department of Surgery, Division of UrologyUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of UrologyUniversity Hospitals, Case Western Reserve University, School of MedicineClevelandUSA

Personalised recommendations